Skip to content
RadBio E22B:Chemo+RT - Synergy & Targeted Agents. episode artwork

May 28, 2025 21 min

RadBio E22B:Chemo+RT - Synergy & Targeted Agents.

from RadOnc Smart Review Hosted by Abass Conteh

In our last episode, we laid out the broad principles of combining chemotherapy with radiation and surveyed the major classes of traditional cytotoxic drugs. Today, we're taking a closer look at the "why" and "how" of these combinations. We'll explore which specific chemotherapy agents are known to work synergistically with radiation, how their cell cycle specificity plays into this partnership, and importantly, the normal tissue toxicities that can be exacerbated. Then, we’ll shift gears to the exciting realm of molecularly targeted therapies, identifying key targets like EGFR, HER2, VEGF, and PARP, and discussing how agents like Cetuximab, Trastuzumab, Bevacizumab, and PARP inhibitors like Olaparib interact with radiation. We’ll cap it off with a crucial concept: synthetic lethality, particularly as it relates to PARP inhibitors and BRCA mutations.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

RadBio E22B:Chemo+RT - Synergy & Targeted Agents.

0:00 21:50

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RadOnc Smart Review?

This episode is 21 minutes long.

When was this RadOnc Smart Review episode published?

This episode was published on May 28, 2025.

Can I download this RadOnc Smart Review episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.